Momenta Rebuffed By Court in Bid to Block Lovenox Copy

The U.S. Supreme Court turned away an effort by Momenta Pharmaceuticals Inc. and Novartis AG’s Sandoz to halt sales of a competing generic version of the blood-thinner Lovenox.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.